Literature DB >> 33867889

Cost-Effective Treatments for Irritable Bowel Syndrome.

Eric D Shah1.   

Abstract

Entities:  

Year:  2020        PMID： 33867889      PMCID： PMC8040909     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  Cost Effectiveness of Biomarker Tests for Irritable Bowel Syndrome With Diarrhea: A Framework for Payers.

Authors:  Christopher V Almario; Benjamin D Noah; Alma Jusufagic; Daniel Lew; Brennan M R Spiegel
Journal:  Clin Gastroenterol Hepatol       Date:  2018-03-27       Impact factor: 11.382

2.  Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy.

Authors:  Eric D Shah; Sameer D Saini; William D Chey
Journal:  Clin Gastroenterol Hepatol       Date:  2019-03-01       Impact factor: 11.382

3.  A Predictive Model to Estimate Cost Savings of a Novel Diagnostic Blood Panel for Diagnosis of Diarrhea-predominant Irritable Bowel Syndrome.

Authors:  Mark Pimentel; Chris Purdy; Raf Magar; Ali Rezaie
Journal:  Clin Ther       Date:  2016-05-31       Impact factor: 3.393

4.  Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.

Authors:  Ali Rezaie; Zeev Heimanson; Richard McCallum; Mark Pimentel
Journal:  Am J Gastroenterol       Date:  2019-12       Impact factor: 10.864
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.